The U.S. Food and Drug Administration (FDA) recently concluded that the benefit of using gadolinium-based MRI contrast agents outweighed any potential risks. However, after consulting with the Medical Imaging Drugs Advisory Committee, the FDA is now committed to alerting healthcare professionals and patients about gadolinium retention by the body. Health care professionals will be asked to consider the retention characteristics of each agent when choosing one for patients who may be at higher risk for gadolinium retention. High-risk patients include those requiring multiple lifetime doses, pregnant women, children and patients with inflammatory conditions. Health care professionals will be asked to minimize repeated gadolinium-based contrast studies when possible, especially when spaced closely together. Prior to receiving gadolinium-based contrast, every patient, parent and caregiver will be asked to read the new Medication Guide which will explain the possible risks. This group of individuals are being advised to notify their doctor if they are pregnant or may be pregnant, the date of their last MRI with gadolinium, if they have had repeated scans with gadolinium and if they have any kidney problems. The FDA is encouraging healthcare professionals and patients to report adverse events or side effects from gadolinium-based contrast agents to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program. To read more about this latest update click here: https://www.pharmpro.com/news/2017/12/fda-issues-warning-over-gadolinium-based-contrast-agents